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Abstract
Physicians in the field of respiratory medicine are particularly concerned about the availability of a reliable diagnostic tool to 
investigate respiratory allergy. Usually, basophils are easy to obtain from peripheral blood and therefore they represent a repro-
ducible model to assess allergy in individuals. Cell assays called basophil activation tests (BATs) are widespread tools for allergy 
diagnosis and are easily available in most of the medical labs. The strategy by which basophils are captured in a flow cytometry 
protocol has met many suggestions, recommendations and experimental novelties in recent years, yet the debate needs to be 
further expanded. Concerns still remain about the suitability of the many approaches to make the basophil activation test (BAT) 
an excellent and practical tool to diagnose allergy, while improving its analytical performance. This technical report describes 
the methodological aspects of the use of the protocol adopting the panel CD45dim/CD123bright/HLA-DRneg to gate basophils in flow 
cytometry, trying to highlight the main biases related to an incorrect use of this protocol.
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Introduction 
Airway allergy is a major cause of exacerba-
tion of respiratory pathologies and in this sense 
a  reliable laboratory tool is fundamental to 
achieve a correct allergy diagnosis. In the very 
recent years, the basophil activation test (BAT) 
has become an outstanding tool to diagnose aller-
gy, though still with some contradictory opinion 
[1]. The way by which basophil activity is inves-
tigated in a BAT involves the adoption of flow 
cytometry methods, which are generally suited to 
capture cells in a virtual electronic approach, not 
physically, and therefore this might generate bias 
and misinterpretation on the real nature of the 
events dotted in a gated channel. In few words, 
flow cytometry shows and counts cells (appearing 
as electronic “dots” in a software screen) on the 
basis of their marker-associated fluorescence, 
so this is an indirect approach to “see” physical 
cells” passing though a  laser detection device. 
Events and dots in a dot plot are not necessarily 
physical single cells, therefore, but their nature 
depends on the features of the fluorochromes-as-
sociated markers, usually expressed on the mem-
brane of the scattered cells, then depending on 
the complex biology of the same leukocytes. If 
we could express this concept with a simplistic 
example, markers are molecules usually up- or 
down-regulated upon activation, which are actu-
ally located on the cell membrane and are easily 
targeted by a fluorochromes-conjugated mono-
clonal antibody, in order to render the marker 
“visible” to the laser system of the flow cytometry 
devices and then to the operator. The same can be 
said for markers used to detect where basophils 
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are (phenotyping), when a complex population of 
cells (whole blood) is examined in flow cytometry. 
This approach would mean that the “amount” of 
markers detected depends on the antibody and 
the fluorochromes performance and also on the 
expression levels of the markers during the assay. 
This issue represents the main technical concern 
of a BAT. A first reason is because researchers 
are endeavoured in finding stable and highly 
specific markers in order to phenotype basophils 
and separate them from other cells in a complex 
milieu such as the whole blood, second because 
in a BAT basophils perfectly distinguished from 
other cells have to be followed up by some highly 
specific markers that should show better than 
other ones the cell dynamics of the allergy activa-
tion [2]. In few words, to “see” (phenotype) baso-
phils in flow cytometry, researchers needs stable 
membrane markers, which do not change their 
expression during the cell activation. Different 
markers should be used to “measure” this activa-
tion. Due to the very complex matter addressed 
in this field, the debate is particularly crowded 
of different and often controversial comments, 
often prompted to expand the discussion in the 
scientific community. 
In a recent paper, for example, some authors 
addressed the reliability of a  flow cytometry 
protocol used to phenotype basophils from pe-
ripheral blood samples. This protocol included a) 
a phenotype-model made by fluorochrome-conju-
gated monoclonal antibodies against CD123 (the 
IL-3 receptor alpha-subunit) and HLA-DR (a MHC 
class II molecule) arranged to gate basophils and 
b) the simple activation marker CD203c to assay 
basophil activation. The authors sustained the 
opinion that the use of CD123 as a single, specific 
marker to capture basophils as CD123pos cells, 
should lead to an underestimation of basophils 
upon cell activation [3, 4]. They concluded that, 
taking into account gating approaches that are 
based solely on CD123, the performance should 
lead to a loss-to-analysis of basophils, particularly 
of the ones that highly express CD63 and CD203c, 
i.e. a cellular loss in flow cytometry upon cell ac-
tivation, resulting in a false-negative outcome for 
the test4. In particular, CD123 is down-regulated 
following basophil activation [4]. 
We believe that the gating strategy using 
CD123 merits some further insight. Previous 
reports have tried to elucidate the role of this 
marker in the phenotyping of basophils for a BAT. 
Therefore, after having come through these inter-
esting observations and comments [4], we decided 
to report some technical notes on the CD123bright/
HLA-DRneg protocol, which we have adopted in 
our research in association with the CD45, in 
order to give a constructive contribution on the 
issue[5, 6]. The new protocol, which allows to 
gate basophils as CD45dim/CD123bright/HLA-DRneg 
cells, is discussed in this article.
Material and methods
Blood collection
Basophils were collected from peripheral 
whole blood of healthy blood donors in sodium 
citrate anti-coagulated specimens from the rou-
tinely running course of the blood transfusion unit 
. When specified, peripheral whole blood sam-
ples were collected in TruCount™ tubes (Becton 
Dickinson, CA, USA), according to the indicated 
procedures and all vials processed within 4 hrs. 
MoAbs, fluorochromes and staining 
procedures
The following monoclonal antibodies con-
jugated with fluorochromes, i.e. CD8-ECD; CD4-
PC7; CD45-APC750; CD3-APC700; CD16-Pacific 
Blue; CD19-KRO; CD38-PC5, CD203c-PE. were 
from Beckman Coulter, Pasadena, CA, USA. The 
following ones, CD123-PeCy5; HLA-DR-APC, 
CD9-FITC; CD63-PE, from BD-Pharmigen Becton 
Dickinson, San Josè, CA, USA. According to the 
Mo-Abs producer’s specifications, an aliquot of 
100 μl was incubated for total 30 minutes and 
when requested activation was carried out ac-
cording to the procedures described in the text. 
About 10 minutes before ending the activation 
step (stopping reaction), the indicated MoAbs 
panels were added, following separate protocol 
patterns. Subsequently reaction was stopped by 
erythrocyte lysing and sample fixation by using 
the Coulter ImmunoPrep® Reagent used with the 
Coulter TQ-Prep Workstation.  
Equipment, FC devices and technical 
performance
Analyses were performed with a Beckman 
Coulter Navios™. FL1-FL10 channels, with three 
lasers, i.e. a) Blue Solid State Diode: 488 nm, 22 
mW laser output; b). Red Solid State Diode: 638 
nm, 25 mW laser output; c) Violet Solid State 
Diode: 405 nm, 40 mW laser output. In the scatter 
analysis the device allowed the resolution process 
of 0.404 μm diameter particles from background 
noise using forward scatter with maximum detec-
tion up to 40 μm diameter particles. Its flow rate 
specification (high yield 25,000 events/sec) was 
ensured by the continuous pressure applied to 
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the sample tube based on user selected flow rates: 
Standard: 780 ml/hour with a carryover: < 0.1%.
Software and data elaboration
Compensation followed cytometer manufac-
turer’s instruction according an off-line procedure 
by applying automated electronics algorithms 
and preset templates, by using bi-parametric 
logarithmic dot plots, gate-specific tubes and 
single-tube data analysis, and optimizing FSC 
threshold and fluorochrome voltage as set up pa-
rameters. Beckman Coulter Navios Tetra System’s 
fully automated instrument set-up. Flow analysis 
was performed using the laser indicated system 
with not less than 10,000 events/sec capability, 
where the throughput of 10 k normal lymphocytes 
is 80 tubes/hour. Mean of fluorescence intensity 
(MFI) for each fluorochrome-labeled monoclonal 
antibody was calculated automatically with the 
cytometer software by averaging the total fluores-
cence of the marker in the basophil gate. As well 
percentage of activated cells was calculated by 
the software considering the CD63-PE bright cells 
counted to the right of a threshold that was estab-
lished including the main peak of fluorescence of 
a sample of resting cells. In order to reduce stand-
ard deviation due to brightly fluorescent cells 
respect to the dimly/negative ones, a logarithmic 
scale and the coefficient of variation to measure 
variability dispersion were used. When the test 
needs further controls, Bigos’ formula to normalize 
brightness over background was also applied [7]. 
Controls
In order to evaluate fluorochrome unspe-
cific staining, isotype controls for anti-IgG1 and 
anti-IgG2a were systematically introduced in the 
preliminary procedure to set up photomultiplier 
and instrument technical parameters; when nec-
essary. A control using a staining procedure car-
ried out without introducing in the assay system 
the fluorochrome of interest was also performed
Statistics
When described, mean ± standard deviation 
(SD) were reported. Parametric distributions, 
when assessed following the Shapiro-Wilk test, 
were evaluated in an ANOVA test (Tukey post hoc 
analysis), with p < 0.05. Data were elaborated 
with an SPSS v. 22.0.0.0 software. 
Results 
Figure 1 shows the electronic capture of ba-
sophils and their purification in flow cytometry, 
according to this approach. Events in the SSClow 
region of the SSC/CD45 plot were selected from 
the CD45dim area (Fig. 1A) and this region was 
subsequently gated for the expression of CD123 
and HLA-DR (Fig. 1B). A distinct events area, 
expressing CD123 at least ten times higher than 
other cells and negative for HLA-DR expression 
(indicated as basophils in Fig. 1B), is also CD4neg, 
CD8neg, CD9pos, CD16neg, CD3neg, CD19neg, CD38bright, 
CD203cpos (Fig. 1, panels C-H). Therefore, the CD-
123bright/HLA-DRneg gated events from the CD45dim 
area are purified basophils6,8. Although basophils 
were gated as CD123pos/HLA-DRneg cells also in 
a paper by other authors published elsewhere [4], 
showing a perfect distinct group of CD123pos/HLA-
DRneg events (see Fig. 1 in ref 4), it is still possible 
that the gate contains CD45pos or CD45bright cells 
expressing CD123, as they are within the SSClow 
region. We therefore approached this issue. 
Figure 2 shows that when selecting baso-
phils from the SSClow region of the SSC/FSC gate, 
one might potentially exclude activated (and 
degranulated) cells while this bias is prevented 
by selecting a CD45dim area for the CD123 gate. 
When cells are selected only through a SSC/ 
/CD123 panel, some basophils might be excluded 
from the analysis. In particular, panel E of Fig-
ure 2 shows that in the SSC/FSC selected area, 
only the CD123pos gating (red dots) was included 
in the area, while many CD123bright events (blue 
dots), probably being activated or degranulated 
basophils, were excluded (Fig. 2 panel E).  
Furthermore, we observed that upon stim-
ulation with 10-7 M formyl-L-Met-L-Leu-L-Phe 
(fMLP) the correct count of cells in the sample, 
gated as CD123bright/HLADRneg cells, according to 
the previously described method of ours using the 
CD45dim population, did not significantly change 
respect to the resting, non activated basophils, 
as calculated using BD-TruCount™ tubes (Becton 
Dickinson, San Jose, CA, ref. 340334, lot 15064). 
Figure 3 shows an exemplificative result of six 
different triplicate samples (1461.5 ± 53.9 SD 
resting cells, 1430.7 ± 65.1 SD activated, p = 
0.65). This result should confirm previously re-
ported evidence about the stability of the CD123 
marker upon basophil activation.
Discussion 
A first, major concern about the suitability 
of the protocol using the only CD123, as previ-
ously reported [4], deals with the kind of strategy 
actually used to perform the electronic capture 
and purification of basophils in flow cytometry, 
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Figure 1. Gating strategy and electronic purification of basophils starting from a CD45dim selected area, exemplificative experiment of five on sodium 
citrate anticoagulated whole blood samples. The region indicated as 45d (A) was gated for the expression of membrane CD123 and HLA-DR and 
a separated area of events (indicated as basophils in the Figure) was recovered (B). This area was CD4neg, CD8neg (C), CD9pos (D), CD16meg (E), CD3neg, 
CD19neg (F), CD38bright (G), CD203cpos (H). 
Samples were treated with N-formyl-L-Met-L-Leu-L-Phe (fMLP) 10-7 M when requested and incubated for a total of 30 minutes, where 10 minutes 
before the end of the incubation fluorochromes-conjugated MoAbs were added according to the producer’s recommendation and standardized lab 
protocols. Subsequently reaction was stopped by erythrocyte lysing and sample fixation procedure by the use of  the Coulter ImmunoPrep® Reagent 
used with the Coulter TQ-Prep Workstation for FC run according to the Beckman Coulter Navios™ flow cytometer, with FL1-FL10 detectors. Internal 
controls and compensation process were accomplished according the instrumental specifications (see text for details) 
i.e. to separate and identify (purify) basophils 
in the gate. The simple use of CD123 as a gating 
marker [3, 4], without introducing in the panel 
further phenotyping markers such as HLA-DR, is 
usually performed following the steps below, in 
the gating strategy: a) selection of a region in the 
SSClow events area (lymphocyte-monocyte region) 
in the SSC/FSC plot; b) gating the CD123expressing 
region (i.e. CD123pos) of the selected SSClow area; c) 
purify cells by selecting events expressing CD123 
[3, 4]. This might be considered quite sufficient to 
purify basophils as cells expressing CD123, which 
later should show also the expression of CD203c, 
which is exclusively expressed by these cells [3, 4]. 
HLA-DR might be used, therefore, simply as 
a confirmatory marker of the gating process, as 
basophils are always negative for the expression 
of HLA-DR [8]. Therefore, some authors are used 
to select an area in the SSClow region of the side 
scatter/forward scatter (SSC/FSC) plot and then 
gate this area simply for the expression of CD123. 
To assess that events are representative of baso-
phils, events within the SSClow/CD123pos gate are 
then examined for the expression of HLA-DR and 
a conclusion that the CD123pos and HLADRneg area 
includes only basophils should emerge [3, 4].
However, any of these approaches should 
contain some possible bias, in our opinion.
Fundamentally, basophils are CD45dim cells 
[6, 8], an issue which has never been previously 
addressed [3]. The SSC/CD45 plot is preferable 
respect to the SSC/FSC one in generating the first 
selection area, because it reduces technical bias. 
In our opinion, any selected area in the SSClow 
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Figure 2. Simulation of the gating strategy with only CD123pos method compared with the CD45dim approach, as described in the text on healthy do-
nor blood samples. (A). A region in the SSC/FSC gate, encompassing a wide FSC area may presumably e included in a SSC/CD123 gating strategy. 
This region is therefore selected (B) and read for the expression of CD123 (C). A selection of the CD123pos region can be gated (see ref 4) but this 
gated region may include two separate areas (W and V), identified in our simulation as R (CD123pos) and U (CD123bright) (D). Panel E shows that in 
the SSC/FSC selected area, only the CD123pos gating was included in the area, while many CD123bright events, probably associated with activated or 
degranulated basophils, were excluded (E). If the same process is performed by starting with a CD45dim selection, only CD123bright cells are included 
in the area (F). These CD123bright events represents basophils, inasmuch both resting and degranulated cells are captured if considering a CD45dim
-CD123bright-HLADRneg protocol. A percentage of degranulated cells usually occurs due to aspecific activation related to handling and pre-analytical 
procedures; SSC — side scatter; FSC — forward scatter
region might contain many ungated CD45pos cells 
expressing CD123 and HLA-DR at various levels, 
such as T and mature B lymphocytes, monocytes, 
pre-B cells, CD56pos-NK cells, myeloblasts, plas-
macytoid dendritic cells and basophils [4, 8]. 
Without the introduction of a  Pan-Leu CD45 
marker, most probably many of these cells are 
captured when selecting the SSClow region, as 
indicated by our results, causing bias in the baso-
phil capture [4]. With the exception of basophils, 
which are CD123bright, the expression of CD123 in 
any of these cells is not completely negative [8]. 
Therefore, we believe that basophils need to be 
initially captured from the CD45 dimmy popula-
tion in the SSClow area of a SSC/CD45 plot, in order 
to reduce this cross-contamination and improve 
their electronic purification [8], as reported also 
in a past paper of ours [6]. 
Furthermore, basophils express markers such 
as CD9, CD13, CD22, CD33, CD36, so they are 
CD25dim and CD38bright, besides to be CD45dim. In 
addition, they do not express CD19, CD16, CD4, 
CD8, CD3 and are actually CD45-dimmer than 
lymphocytes and CD45-brighter than myelo-
blasts, which would mean than in a SSClow/CD45 
gate, basophils are at the left side respect to lym-
phocytes and right to CD34 and CD117 positive 
cells (myeloblasts), which are CD45dimmer than 
basophils, i.e. the CD45 expression order in the 
SSC/CD45 plot is myeloblasts-basophils-lympho-
cytes. All these cells express CD123 and HLA-DR 
at different levels on the membrane, from negative 
to positive (see also Figure 1A red area). Notori-
ously, T-cells and mature B-cells are negative or 
very low expressing CD123 and myeloblasts are 
positive for CD123 but dimmy (i.e.CD123dim), so 
they could affect basophil count as simply CD123 
positive cells, although they are also HLA-DR 
positive. Any gate performed by using initially 
the SSC/FSC plot, most probably introduced cells 
with high SSC, such as lymphocytes and mono-
cytes, which are CD123 weak positive cells but 
are not CD45dim and do not express CD203c. As 
detailed in the Results section, Figures 1 and 2 
would contribute in describing this issue. There-
fore, in this report, we assessed that CD123bright/
HLA-DRneg gated events from the CD45dim area are 
quite presumably purified basophils [5, 6]. 
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Figure 3. Exemplificative experiments showing the absolute cell count in the CD123bright/HLA-DRneg gate using BD TruCount™ tubes. Initially, a CD45dim 
area was selected from TruCount™ tubes containing blood samples from healthy volunteers (A1). Events from this CD45dim area were gated for the 
expression of CD123 and HLA-DR (A2) and values of beads considered for the calculation of the absolute count of basophil in the gate. Basophils 
as CD123bright/HLADRneg events (C), were evaluated for the expression of CD63% (D). Cells treated with 10-7 M fMLP for 30 min at 37°C, then stained 
and blocked as explained in the text, were introduced in the same test, using BD TruCount™ tubes (D1, D2, E, F). Calculations made according to 
the BD TruCount™ methods (beads = 48700), gave results discussed within the text. FC performance with Beckman Coulter Navios™ flow cyto-
meter, with FL1-FL10 detectors. Internal controls and compensation process were accomplished according the instrumental specifications (see text)
Furthermore, the use of the simple CD123, 
particularly when not associated with the more 
specific marker CD203c, has been reported to 
cause some further concern, namely the presump-
tive reduction of CD123 during cell activation. 
Fundamentally, an up- or down-regulation of 
a marker may not result in an over- or underes-
timation of the count of the population. A pos-
sible reduction may be induced by experimental 
conditions, such as an incorrect erythrocyte 
lysis. However, the effect of some lysis reagent, 
such as Pharmlyse, was recently compared with 
other lysis solutions and does not seem to cause 
bias in the leukocyte count in FC [9], although 
previous reports claimed a possible impact on 
immuno-phenotyping caused by different lysis 
protocols and reagents [4, 10]. 
As demonstrated by results in Figure 3, 
we observed that upon stimulation with 10-7 
M formyl-L-Met-L-Leu-L-Phe (fMLP), a bacteri-
al-derived product, the correct count of cells in 
the sample, gated as CD123bright/HLADRneg cells, 
according to the previously described method us-
ing the CD45dim population, did not significantly 
change respect to the resting, non activated ba-
sophils, as calculated using BD-TruCount™ tubes 
(Becton Dickinson, San Jose, CA, ref. 340334, lot 
15064). This result should confirm previously 
reported evidence about the stability of the CD123 
marker upon basophil activation [5, 6]. Besides 
the technical process, lysis reagents, pre-ana-
lytical bias, also the imaging approach might 
lead to bias and the interpretation of a CD123 
downloading upon activation, if cells are not 
correctly gated as CD45dim leukocytes [4]. For 
example, the use of density-weighted diagrams 
may generate some misinterpretation in the read-
ing of CD123pos cells, causing an apparent loss 
of events. Yet, a  reliable normalized functional 
measure of reagent brightness is the so-called 
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“stain index”, which is defined as D/W, where D 
is the difference between positive and negative 
cell populations, and W is equal to 2 SD of the 
negative population. Therefore, the way by which 
plots are shown might create bias in the selection 
process. A further bias is that events in the plot 
cannot be directly considered cells, at least when 
counted in a gate. As events depend on fluores-
cence performance, the methodological approach 
of flow cytometry, miight play a major role also 
in this debate. Furthermore, the different choice 
of fluorochromes may affect test performance, 
particularly if used as conjugates of phenotyping 
markers. It is probably a good idea to use a fluo-
rochrome-combination which does not interfere 
with the signal of the activation markers used, 
for example: CD123-APC, HLA-DR (and lineage 
markers)-PacBlue and CD203c-PE.
In this respect, when the same antibody is 
conjugated to various dyes, their stain indexes 
may be compared to reach an idea of the relative 
brightness of the dyes on a particular FC instru-
ment. For example, on BD instruments, FITC has 
a stain index of about 50, PerCp-Cy5.5 ≈ 80 while 
PE ≈ 250 but FITC has a relevant spillover on PE, 
which is usually conjugated with the activation 
marker CD203c [1, 11, 12]. moreover, it is wide-
ly known that, in order to optimize gating, bias 
from fluorescence spillover must be considered if 
the compensation process has not been properly 
done. This should not be a fundamental concern 
in a CD123-based gating strategy, as previously 
reported [4], but it may have an effect if the gat-
ing marker is widely shared with non-basophil 
cells. Levels and brightness of fluorochromes in 
different companies might also cause differenc-
es in the observed effects by different research 
groups and in conclusion expression of basophil 
markers and BAT performance depend on a good 
gating approach [2]. 
According to some author, activation may 
even up-regulate HLA-DR and down-regulates 
CD123 in basophils, yet these cells are notorio-
usly negative for HLA-DR membrane expression 
[4, 5, 13]. If CD123 is really down-regulated by 
activation, it would be very interesting to assess if 
a gating strategy using CCR3 (CD193), the eotaxin 
receptor, might bear the same concern reported 
by others elsewhere [3, 4], as CCR3 appears to be 
down-regulated upon basophil activation [2, 14, 
15]. Interestingly, some authors reported a paper 
where a phenotyping protocol using a combi-
nation of CD123 and CCR3 markers, improved 
significantly the performance of BAT, respect to 
the only CD123 [16].  
This approach should affect also the way 
by which any activation marker is interpreted to 
evaluate activation in the in vitro basophil test. 
Which is therefore the bet way to gate and inve-
stigate basophils? This may depend also on those 
markers used to test activated basophils.
Some authors gated events from the lowest 
region (SSClow) of the SSC/FSC plot for the CD203c 
expression, which is notoriously an activation 
marker, and realized that these events included 
only CD123bight/HLA-DRneg cells, i.e. basophils [4]. 
Then, by comparing the activation behaviour 
with CD63 and CD203c of either cells gated as 
CD123pos/HLA-DRneg or as CD203cpos, no significant 
difference was reported [4]. Someone therefore 
concluded that the introduction of the CD203c 
marker to gate basophils, should improve the 
diagnostic accuracy of BAT from 91% to 97% 
[3, 4, 17]. Therefore, according to the different 
authors, the reliability of the CD123/HLA-DR 
protocol seems to need the inclusion of CD203c in 
the phenotyping process, in order to better ensure 
the electronic capture of basophils during the 
activation step and reduce the apparent cell loss 
in the gate due to CD123 down-regulation [3, 4]. 
However, we have assessed with BD TruCo-
unt™ tubes that CD123 does not change its expres-
sion during basophil activation, yet evidence 
that CD203c moves its expression pattern upon 
activation was already reported [6]. This trend 
confirmed  previous data from our lab, perfor-
med with a BD-FACScanto flow cytometer [5, 6]. 
While basophils remained HLA-DRneg, despite the 
different kind of stimuli adopted, CD123-PECy5 
showed always a bright appearance, with MFI 
values in the range 104– 2 × 104, i.e. at least ten 
(101) times the basal positive expression of CD123 
and with the absence of significant regression in 
a  linear regression test from the CD123-PECy5 
expression in resting, non activated control. This 
trend was confirmed also for the basophil events 
dots in the gate [6]. On the contrary, if events are 
gated with a CD123-FITC from the SSClow region 
of the SSC/FSC plot, instead from a CD45dim area, 
all CD123-expressing cells cannot be considered 
only basophils and during the evaluation of CD63 
or CD203c, an apparent loss can be observed 
due to the inability of the non basophilic CD-
123-expressing cells to express and up-regulate 
CD63 or CD203c. 
Finally, a loss of degranulated basophils was 
also demonstrated (see Fig. 2). These non baso-
philic cells, previously included in the gate, sho-
uld show a low or dimmy expression of CD123, 
leading to a possible misinterpretation (compa-
Advances in Respiratory Medicine 2017, vol. 85, no. 4, pages 193–201 
200 www.journals.viamedica.pl
re Fig. 2E, F). Apparently, the introduction of 
CD203c to gate events from an SSC/FSC plot and 
then purifying these cells as CD123bright/HLA-DRneg, 
might appear pleonastic, as BAT diagnostic appro-
aches based on CD203c as the only phenotyping 
marker are reported in the literature [18]. CD203c 
is up-regulated during either an IgE-mediated or 
a non-IgE mediated activation [6]. Using CD203c 
as a phenotyping marker should prevent its use 
as an activation marker, although the authors 
showed its use both in gating and activation [4]. 
During the evaluation of the expression of CD63 
in CD203c gated cells, the fluorescence intensity 
distribution of the CD203c used as an activation 
marker, may be completely shifted to higher valu-
es in activated cells respect to non activated ones 
[5] and this may prevent a correct evaluation of 
the percentage of CD63pos cells (calculated on the 
total gated basophils) [5, 19].   
Basophils gated with CD203c-PE and then 
purified as CD123bright/HLA-DRneg, when evaluated 
for the expression of CD63 and CD203c upon ac-
tivation with formyl-L-Met-L-Leu-L-Phe (fMLP), 
show an increase in the number of basophils 
expressing CD63 [4, 6]. This circumstance, shown 
by using the only CD123, is perfectly comparable 
to the one previously published where the simple 
gating protocol CD45dim/CD123bright/HLA-DRneg was 
adopted, practically suggesting that the introduc-
tion of CD203c is quite useless [4, 6]. 
Conclusions
These results should confirm that CD123 is 
expressed by basophil in a bright, constitutive 
form and probably changes in a very negligible 
way upon either an IgE- or non IgE-mediated 
activation. 
According to our opinion, the best perfor-
mance process should encompass the following 
bullet points:
1) Basophils should be gated from an initially 
selected CD45dim region in a SSC/CD45 plot, 
that includes also activated (“degranulated”) 
basophils, contrarily to a SSC/FSC plot; 
2) The expression of CD123 does not change the 
absolute basophil count in the gate upon ac-
tivation, as assessed with TruCount™  tubes;
3) The use of CD203c within the CD123/HLA
-DR phenotyping protocol upon activation 
with fMLP resulted in a CD63/CD203c dot 
plot perfectly similar to the one obtained by 
gating basophils only with a CD123/HLA-DR 
approach (compare Fig. 5b ref 4 with Fig. 4 
ref. 6).
4)  CD203c used as a gating marker may cause 
bias in the apparent basophil count in the 
gate upon activation and cannot be used at 
the same time as an activation marker. 
Our final opinion, confirmed by experimental 
tests, is that CD123 does not significantly change 
upon basophil activation and that bias in the cell 
count are mainly generated by gating basophils 
from a SSC/FSC and by gating cells with activa-
tion markers. 
The reported decrease in cell count in the 
gate might be an artefact due to the gating process 
and it is not confirmed by our studies [3, 4].
BAT is a cellular assay used to ameliorate our 
ability to diagnose allergy and hypersensitivity 
reactions and therefore the debate about its re-
liability and suitability for clinics still represents 
a  fundamental activity of current research in 
allergy and immunology. Further research should 
improve our knowledge about basophil biology 
and its role in the immune system. 
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